Author's response to reviews

Title: DNA Methylation Alterations in Grade II- and Anaplastic Pleomorphic Xanthoastrocytoma

Authors:

Ramón Martínez (ramon.martinez@med.uni-goettingen.de)
Francisco Javier Carmona Sanz (carmonasfj@gmail.com)
Miguel Vizoso (mvizoso@idibell.cat)
Veit Rohde (nchisekr@med.uni-goettingen.de)
Matthias Kirsch (matthias.kirsch@zfn.uni-freiburg.de)
Gabriele Schackert (gabriele.schackert@uniklinikum-dresden.de)
Santiago Ropero (santiago.ropero@uah.es)
Werner Paulus (werner.paulus@uni-muenster.de)
Alonso Barrantes (alonso.barrantes@med.uni-goettingen.de)
Antonio Gomez (agomezm@idibell.cat)
Manel Esteller (mesteller@idibell.cat)

Version: 7 Date: 4 March 2014

Author's response to reviews: see over
Ms. Roselyn Remoto

Journal Editorial Office

Dear Ms Remoto,

Please find attached a revised version of the manuscript entitled “DNA Methylation Alterations in Grade II- and Anaplastic Pleomorphic Xanthoastrocytoma” that has recently been accepted for publication in *BMC Cancer*.

According to your request, I have included all the changes in the main text. Please find a detailed point-by-point description of the changes made.

1. Could you kindly confirm whether you received ethics committee approval for your study and please include the name of the ethics committee in your method section.

2. Please also confirm whether you received consent to publish specific patient characteristics or the images in this report from patients and please add a statement including this in your manuscript,

Points 1, 2 and 3 were modified on the Patient samples and controls paragraph, within the Material and Methods section.

The study was approved by the Ethics Committee of the School of Medicine, University of Göttingen (project number 11/8/13), and patients provided informed consent to publish the images and clinical information. All PXA (n=13 tumors, 12 patients) and GBM patients (n=87) had undergone surgery with the goal of maximal possible tumor resection. One anaplastic PXA (PXA-5) was the local relapse of a grade II PXA (PXA-4), one year after complete tumor resection (*Table 1*).

3. Please also make sure you anonymize table 1.

All patient IDs have been appropriately codified to ensure privacy protection.

4. Please also provide an availability of supporting data section after your methods.

There is no additional supporting data apart from the supplementary files that have been submitted and are referenced along the text.

We thank the Editor and the Reviewers for their positive comments regarding the interest of our manuscript and their very helpful remarks and suggestions. I enclose the revised version of the manuscript with the hope that it will prove fully acceptable.

Best regards,

PD Dr. med. Ramón Martínez-Olivera